الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 180 |  |  |
| | | from | 180 | | |
Abstract
CD40 and its ligand (CD40L) are glycoproteins from the tumor necrosis factor family (Freedman, 2003). The CD40–CD40 ligand system is widely distributed on a variety of leukocytic and nonleukocytic cells, including endothelial and smooth-muscle cells, (Schonbeck et al., 2001) and on activated platelets, (Henn et al., 1998).
CD40 ligand also occurs in a soluble form that is fully active biologically, termed soluble CD40 ligand which is shed from stimulated lymphocytes and is actively released after platelet stimulation ( Henn et al., 2001).
Soluble CD40 ligand is proinflammatory for endothelial cells and promotes coagulation by inducing expression of tissue factor on monocytes and endothelial cells (Urbich et al., 2001).Moreover, soluble CD40 ligand contains a KGD )Lys-Gly-Asp) sequence, a known binding motif that is specific for the major platelet integrin aIIbβ3 (Graf et al., 1995).
Indeed, CD40 ligand has been demonstrated to be an aIIbβ3 (glycoprotein IIb/IIIa) ligand and a platelet agonist and to be necessary for the stability of arterial thrombi (Andre et al., 2002a).
The aim of this work was to evaluate levels of sCD40L in smokers with acute MI versus non-smokers to identify the patients who are likely to benefit from treatment with the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor antagonists.
The present study was conducted on 79 subjects, 59 males and 20 females since April 2012 to May 2013, subdivided into two groups. Group I: This group included 60 patients with AMI (ST segment elevation and non-ST segment elevation), including 45 males and 15 females and have been admitted to Coronary Care Unit in Benha University Hospital.